Curevo Vaccine

We are presenting data on our Phase 2 trial of amezosvatein versus Shingrix for the prevention of herpes zoster at IDWeek 2024 underway in Los Angeles. It is poster # 597, available October 17th (tomorrow) from 12:15 to 1:30pm PDT in Hall J & K. We issued a press release about the data this morning. https://lnkd.in/eGvkqsqa Dr. William Smith, the primary investigator on the Phase 2 trial, had this to say about the data: "Shingles is a very serious disease with effects often outlasting the painful rash. If these amezosvatein data are confirmed in Phase 3 trials and the vaccine is approved, I expect its lower reactogenicity rates will help get more people protected against shingles.”

We are #hiring.  The CMC Operations Team at Curevo Vaccine is looking to hire a Sr. CMC Manager, CMC Operations.  Your role will involve driving the CMC programs at CDMOs for development, scale-up, cGMP manufacturing, process characterization, and qualification for phase III clinical studies and commercial supply. If you are passionate about vaccine development, Curevo Vaccine is the place for you. Reach out to me directly, Sabreena.Tressler@tsptalent.com or apply using the link – https://lnkd.in/e-YTzTbH #adjuvantvaccines #vaccinedevelopment #infectiousdisease #processdevelopment #latephasedrugdevelopment #biologics #drugproductprocessvalidation #proteinproduction #proteinpurification #formulationdevelopment #lyophilizedrecombinantprotein

Curevo will be attending two global investor healthcare conferences in June. We'll be attending the Jefferies Global Healthcare Conference June 4-6 in New York. 1:1 slots are available and we're also available to meet outside the conference for those in the NYC area. June 10-13, we're presenting at the Goldman Sachs' 45th Annual Global Healthcare Conference in Miami. 1:1s are available for those attending the conference.

Curevo will be attending two global investor healthcare conferences in June. We'll be attending the Jefferies Global Healthcare Conference June 4-6 in New York. 1:1 slots are available and we're also available to meet outside the conference for those in the NYC area. June 10-13, we're presenting at the Goldman Sachs' 45th Annual Global Healthcare Conference in Miami. 1:1s are available for those attending the conference.

Curevo’s CEO, George Simeon, will be presenting at the Citizens JMP Life Science Conference in NYC on May 14 at noon in Room B of the conference. George and David Miller, Curevo’s Sr. Dir. Of Strategic Communications, will be available Monday and Tuesday for 1:1s with investors at the conference or in the NYC area.

We’re #hiring a new Statistical Programmer, Biometrics in Bothell, Washington. Apply today or share this post with your network.

Congrats for George Simeon and the rest of the Curevo Vaccine team on their positive Phase II data readout presented here at the J.P. Morgan healthcare conference. Christopher Gartin Mario Barro

We are excited to share the results of our Phase 2 trial this morning, ahead of our Wednesday presentation in the private track at the #JPM24 conference beginning Monday in San Francisco. The entire Curevo team would like to thank the investigators, and especially the participants in this trial, for their help in making this happen. Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix   Positive data from this 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including a 100% vaccine response rate. Amezosvatein also met the primary safety endpoint, with lower local and systemic adverse events in this trial compared to Shingrix. Amezosvatein to enter global Phase 3 trials in 2024  

We're excited to announce Curevo Vaccine will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th, at 4pm PST #JPM24 #JPM24privatetrack